Seladelpar NDA Submitted to FDA for Primary Biliary Cholangitis
The New Drug Application submission is supported by data from a pair of phase 3 studies, a long-term open-label study, and prior phase 2 studies. Cymabay has also requested Priority Review of the NDA.
Source: hcplive.com